Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
| Revenue (TTM) | $50.03B |
| Gross Profit (TTM) | $35.28B |
| EBITDA | $18.24B |
| Operating Margin | 33.80% |
| Return on Equity | 44.00% |
| Return on Assets | 10.90% |
| Revenue/Share (TTM) | $24.54 |
| Book Value | $11.45 |
| Price-to-Book | 5.51 |
| Price-to-Sales (TTM) | 2.54 |
| EV/Revenue | 3.223 |
| EV/EBITDA | 10.22 |
| Quarterly Earnings Growth (YoY) | -2.80% |
| Quarterly Revenue Growth (YoY) | 6.90% |
| Shares Outstanding | $2.04B |
| Float | $2.04B |
| % Insiders | 0.10% |
| % Institutions | 84.62% |
Volatility is currently contracting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AHA--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos.
A blockbuster blood thinner is about to lose $1.5 billion to $2 billion in sales, and the debt pile hasn't gone away. Retirees counting on Bristol Myers Squibb's payout need to know which numbers actually matter before 2027 arrives.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie is successfully navigating a critical transition period as newer immunology drugs offset revenue declines from legacy products. Bristol Myers Squibb offers a high-margin portfolio focused on oncology and hematology with a significantly lower valuation multiple.
Bristol Myers Squibb gains 3% after beating third-quarter estimates, as its Growth Portfolio and promising pipeline support revenue prospects despite generic competition.
Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic ahead of looming patent cliffs. BMY's Growth Portfolio now comprises ~59% of revenues, with 8 medicines annualizing above $1 billion, partially offsetting legacy portfolio declines. DCF analysis values BMY at $61.19 per share, nearly matching the current price, highlighting limited upside even with near flat forward revenue growth.
BMY raises its 2026 revenue outlook on strong Growth Portfolio sales, even as earnings pressure, patent expirations and drug launch challenges remain in focus.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Bristol Myers Squibb NYSE: BMY raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining a series of clinical readouts and manufacturing investments intended to support its next generation of launches.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMY and any ticker you trade — then tracks every position and per-strategy win rate.
